Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Summary

Rona Therapeutics granted Roche an exclusive worldwide license for its investigational ALK7-targeting RNAi candidate for obesity and metabolic diseases. This partnership represents a significant validation and out-licensing opportunity for Rona's obesity/metabolic disease program to a major pharmaceutical company.